Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Moonshiner592on May 23, 2021 11:58am
195 Views
Post# 33255312

RE:RE:3rd day

RE:RE:3rd day

AngelaL wrote: I think you're correct. It's clear, at this point, that there will be a reverse split approved at the shareholder meeting in less than four weeks and that this will increase the share price to 60-80 cents. This will make it impossible for the share price to fall below the five cent cutoff necessitated by the TSXV to sell shares. Accordingly, the shorters will no longer have the ability to drive the company into bankruptcy by exploiting the five cent rule to prevent the company from selling equity to raise capital. Shorters must be aware of that and are now covering their positions and getting out. The true valuation of Claritas is probably around $80 million Canadian so we should expect in my view a doubling of the market valuation during the period running up to the shareholder meeting, followed by another doubling immediately thereafter. 


You go girl!!!

To the Shorts - Beware... if you stick around .. it will suck royally to be you!

To the constant bashers:  Prepare for defeat.. 
 

<< Previous
Bullboard Posts
Next >>